Evaluating the exact influence of TKI-therapy in patients with BCR-ABL+ CNS leukemia is difficult as these patients receive a combined treatment strategy consisting of TKI plus other therapeutic measures in routine clinical practice. The gene discussed is ABL1; the disease is central nervous system leukemia.